Sugi Predict

Sugi Predict / Compounds / Rotenone

Rotenone

Rotenone

SCHEMBL43319

C1=NOCC1.C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 11/20 0.83
▸ MAPT P10636 8/20 0.83
▸ SMN1; SMN2 Q16637 8/20 0.83
▸ ALDH1A1 P00352 5/20 0.83
▸ KDM4E B2RXH2 5/20 0.83
▸ TDP1 Q9NUW8 5/20 0.83
▸ CYP2C19 P33261 4/20 0.83
▸ LMNA P02545 4/20 0.83
▸ MAPK1 P28482 4/20 0.83
▸ TP53 P04637 4/20 0.83
▸ USP2 O75604 4/20 0.83
▸ TSHR P16473 3/20 0.83
▸ MT-ND4 P03905 3/20 0.83
▸ CYP2C9 P11712 2/20 0.83
▸ NPC1 O15118 2/20 0.83
▸ RAB9A P51151 2/20 0.83
▸ CYP1A2 P05177 2/20 0.83
▸ HPGD P15428 2/20 0.83
▸ GMNN O75496 1/20 0.83
▸ ABCB11 O95342 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rotenone SCHEMBL1707595 0.98 CYP3A4 (0.79) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL29388856 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL13845713 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL29351552 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL13926662 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL9815546 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL19019920 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL42253 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL20152380 0.91 CYP3A4 (1.00) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E
Rotenone SCHEMBL5490007 0.90 CYP3A4 (0.98) CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117320732-A Non-autologous multi-stress cancer cells for cancer vaccination and treatment and uses thereof 屏蔽药房 2023-12-29 — — CN claimed
EP-2686438-B1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFOR VENTANA MED SYST INC (US) 2018-04-18 — — EP claimed
US-9562259-B2 Method of analyzing chromosomal inversions VENTANA MEDICAL SYSTEMS, INC. (US) 2017-02-07 — — US claimed
EP-2442107-B1 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MED SYST INC (US) 2014-03-12 — — EP claimed
EP-2686438-A1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE Ventana Medical Systems, Inc. (US) 2014-01-22 — — EP claimed
CN-103534359-A A method of analyzing chromosomal translocations and a system therefore VENTANA MED SYST INC 2014-01-22 — — CN claimed
EP-2539355-A1 POLYTAG PROBES Ventana Medical Systems, Inc. (US) 2013-01-02 — — EP claimed
EP-2539466-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES Ventana Medical Systems, Inc. (US) 2013-01-02 — — EP claimed
US-20120301885-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES TANG LEI (US) 2012-11-29 — — US claimed
US-20120301886-A1 POLYTAG PROBES VENTANA MEDICAL SYSTEMS, INC. 2012-11-29 — — US claimed
WO-2012123387-A1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 — — WO claimed
US-20120237930-A1 METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE VENTANA MEDICAL SYSTEMS, INC. 2012-09-20 — — US claimed
EP-2444807-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE Ventana Medical Systems, Inc. (US) 2012-04-25 — — EP claimed
WO-2011106495-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES VENTANA MEDICAL SYSTEMS, INC. (US) 2011-09-01 — — WO claimed
WO-2011106583-A1 POLYTAG PROBES VENTANA MEDICAL SYSTEMS, INC. (US) 2011-09-01 — — WO claimed
EP-2078197-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE Ventana Medical Systems, Inc. (US) 2009-07-15 — — EP claimed
WO-2008063378-A9 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MED SYST INC (US) 2008-07-31 — — WO claimed
WO-2008063378-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MEDICAL SYSTEMS, INC. (US) 2008-05-29 — — WO claimed
US-11906523-B2 Signaling conjugates and methods of use VENTANA MEDICAL SYSTEMS, INC. (US) 2024-02-20 — — US disclosed
WO-2008063378-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MEDICAL SYSTEMS, INC. (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11906523-B2 Signaling conjugates and methods of use CABLES1, ILK, BCR CYP3A4 4698/4885MAPT 4802/4885SMN1; SMN2 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.